Pharma
Merck Makes $10B Acquisition of Verona Pharma to Bolster Respiratory Portfolio
Merck; Verona Pharma; acquisition; Ohtuvayre; COPD; respiratory disease; Keytruda patent; biotech; pharmaceutical industry
TIGIT Turmoil: How Pharma Burned Billions on Failed Immuno-Oncology Projects
TIGIT; immuno-oncology; failed clinical trials; pharma investment loss; Gilead; GSK; Bristol Myers Squibb; Novartis; Merck; Roche; iTeos; Arcus Biosciences; tiragolumab; belrestotug
Royalty Pharma Commits $2 Billion to Revolution Medicines for RAS Cancer Drug Development
Royalty Pharma; Revolution Medicines; daraxonrasib; $2 billion funding; RAS cancer; synthetic royalty; secured debt; clinical development; oncology; biotech funding
Trump Administration Considers Limits on Direct-to-Consumer Drug Advertising
Trump administration; DTC drug advertising; pharmaceutical regulation; drug pricing; executive order; health policy; pharma marketing
Shrinking Budgets and Rising Targets Pile Pressure on Pharma Marketers: Survey Highlights 2025 Challenges
pharma marketing; shrinking budgets; rising targets; 2025 survey; healthcare marketing trends; budget constraints; innovation; marketing pressure
Schott Pharma Invests Over €100M in New Sterile Cartridge Facility at Hungary Site
Schott Pharma; Hungary; sterile cartridge facility; €100 million investment; RTU cartridges; pharma packaging; manufacturing expansion; Lukácsháza; GLP-1 drugs; diabetes; automation; environmental impact
Science-Led Storytelling Takes Center Stage in Pharma Communications (June 2025)
pharmaceutical communications; science-led storytelling; pharma marketing; patient engagement; trust and transparency; Cheryl Lubbert; Reverba Global
FDA Advisory Committee Narrowly Votes Against UroGen’s Bladder Cancer Drug, Calls for Further Studies
FDA; UroGen Pharma; UGN-102; bladder cancer; Oncologic Drugs Advisory Committee; mitomycin; RCT; non–muscle invasive bladder cancer; clinical trials
BioMarin Acquires Inozyme Pharma for $270M, Gaining Phase 3 Rare Disease Therapy
BioMarin; Inozyme Pharma; acquisition; rare disease; INZ-701; ENPP1 Deficiency; enzyme replacement therapy; Phase 3 clinical trial
Mayne Pharma Faces FDA Action Over ‘Misleading’ Drug Safety Claims Ahead of $430M Buyout
Mayne Pharma; FDA; misleading claims; Nextstellis; birth control pill; drug safety; buyout; Cosette Pharmaceuticals